SCHEMBL2820331

SCHEMBL2820331

COc1ccc(C(=O)Nc2ccc(C(C)(CN)CO)cc2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
ALDH1A1 P00352 4/20 0.55
PKM P14618 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MAPT P10636 3/20 0.55
TP53 P04637 2/20 0.55
NPC1 O15118 6/20 0.53
RAB9A P51151 5/20 0.53
NQO2 P16083 1/20 0.52
CASP3 P42574 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
USP2 O75604 1/20 0.52
ROCK2 O75116 1/20 0.51
POLB P06746 3/20 0.50
NR1H4 Q96RI1 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814428 0.87 KMT2A (0.60) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL2820329 0.85 KMT2A (0.57) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL27775777 0.84 MEN1 (0.60) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL2814726 0.83 KMT2A (0.58) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL7301440 0.82 SMN1; SMN2 (0.78) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL2814444 0.82 KMT2A (0.62) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL2814725 0.81 KMT2A (0.58) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL27775817 0.80 KMT2A (0.64) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL2816734 0.80 MAPT (0.62) KMT2AMEN1ALDH1A1PKMSMN1; SMN2
SCHEMBL2817388 0.77 PKM (0.55) KMT2AMEN1ALDH1A1PKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US claimed
EP-2134676-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE Addex Pharma SA (CH) 2009-12-23 EP claimed
WO-2008117175-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2008-10-02 WO claimed
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US disclosed
EP-2134676-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE Addex Pharma SA (CH) 2009-12-23 EP disclosed
WO-2008117175-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE FSHR, GNRHR, SHBG KMT2A 1767/4885MEN1 150/4885ALDH1A1 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.